| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product name | Cyproterone acetate |
| CAS No. | 427-51-0 |
| Molecular Formula | C24H29ClO4 |
| Molecular weight | 416.94 |
| Shelf life | 2 years |
Cyproterone acetate (INN, USAN, BAN, JAN; abbreviated as CPA, sold under brand names such as Androcur and Cyprostat) is a synthetic steroidal antiandrogen, progestin, and antigonadotropin. Cyproterone acetate is primarily used in the treatment of androgen-related conditions by virtue of its ability to suppress androgenic activity in the body, an effect which it mediates by preventing endogenous androgens from interacting with the androgen receptor and by suppressing androgenbiosynthesis.
Product Usage CPA has been in use as an antiandrogen since 1964, and was the first antiandrogen introduced for clinical use. CPA has been approved for the treatment of prostate cancer, precocious puberty, androgen-related dermatological conditions (such as acne, seborrhea, hirsutism, and androgenic alopecia), and to reduce sex drive in sex offenders. Combination formulations of CPA with ethinyl estradiol (a formulation sometimes referred to as co-cyprindiol) have been available as contraceptives since 1997. Other uses of CPA include the treatment of benign prostatic hyperplasia, priapism, hypersexuality, paraphilias, hot flashes, and hyperandrogenism in women.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}